Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Astrazeneca Plc

(NYSE: AZN)
Add to Portfolio
-0.26 (-0.59%)
as of Oct 18, 2019

Last 43.87
Change -0.26 (-0.59%)
Open 44.18
Prev. Close 44.13
Today's Range
43.67
44.20
52wk Range
35.30
46.22
Volume 1,654,200
Avg Volume 2,910,520
Sector SIC-2834 Pharmaceutical Preparations

Perfomance Comparison

Name Today 3-Month 1-Year
AZN -0.59% -0.61% +12.63%
DJIA -0.95% +1.49% +5.48%
S&P 500 -0.39% +1.64% +7.85%

Key Statistics

Annual EPS 0.87
Dividend Yield 1.99%
P/E Ratio 22.40
Market Capitalization, $K 115,786,703
Weighted Alpha +13.70
Standard Deviation -0.52
Profit Margin 24.69%
Beta 0.47

Growth Rates

YTD +15.51%
1-Year +11.88%
3-Year +42.81%
5-Year +25.13%
10-Year +95.37%

Opinion

Sell Hold Buy

Recent Headlines

[Fam-] Trastuzumab Deruxtecan Granted FDA Priority

BusinessWire via COMTEX - Thu Oct 17, 07:00AM EDT
AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced that the US Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for [fam-] trastuzumab deruxtecan (DS-(full story)
AZN: 43.87 (-0.26), DSNKY: 62.5200 (-0.6300)

ImaginAb signs multi-party collaboration agreement

PR Newswire via COMTEX - Mon Oct 14, 02:00AM EDT
ImaginAb, Inc., a leading clinical-stage immuno-oncology imaging company, today announced the signing of a multi-party collaboration agreement with AstraZeneca (LSE/STO/NYSE: AZN), Pfizer Inc. (NYSE: PFE) and Takeda Pharmaceutical(full story)
AZN: 43.87 (-0.26), PFE: 36.46 (unch)

AstraZeneca Launches Signature STEM Program to Empower

BusinessWire via COMTEX - Mon Oct 07, 07:48AM EDT
AstraZeneca today announced the launch of a new STEM -- science, technology, engineering, and mathematics -- program in partnership with Learning Undefeated and Discovery Education, with the mutual goals of inspiring the next gene(full story)
AZN: 43.87 (-0.26)

FASENRA(R) (benralizumab) Approved in the US for

BusinessWire via COMTEX - Fri Oct 04, 07:00AM EDT
AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved the self-administration of FASENRA(R) (benralizumab) in a pre-filled, single-use auto-injector (the FASENRA Pen(TM)).(full story)
AZN: 43.87 (-0.26)

Healthcare Companies Seek Innovative Ways to Combat

PR Newswire via COMTEX - Tue Oct 01, 09:00AM EDT
Many underdeveloped regions around the world are ravaged by diseases due to their lack of proper healthcare. And despite ongoing medical advancements, researchers have noted that new diseases are continuing to emerge. The Institut(full story)
GSK: 42.53 (+0.06), INMB: 4.35 (+0.13), LLY: 108.64 (+0.18), BMY: 53.03 (+0.61), AZN: 43.87 (-0.26)